5. Science and Technology for Disease Control: Past, Present, and Future

Table 5.1: Pharmacogenomics

Pharmacogenomics
GeneDrugClinical consequence
Drug metabolism
NAT-2Isoniazid, hydralazine, procainamide, sulfonamidesNeuropathy, lupus erythematosus
CYP2D6Beta-blockers, antidepressants, codeine, debrisoquine, antipsychotics, many othersArrhythmias, dyskinesia with antipsychotics, narcotic effects, changes in efficacy, many others
CYP2C9Tolbutamide, phenytoin, nonsteroidal anti- inflammatoriesAnticoagulant effects of warfarin modified
RYR-1Halothane and other anestheticsMalignant hyperthermia
Protection against oxidants
G6PDPrimaquine, sulfonamides, acetanilide, othersHemolytic anemia
Drug targets
ACECaptopril, enalaprilModified response to treatment of cardiac failure, hypertension, renal disease
HERGQuinidineCardiac arrhythmia (long Q-T syndrome)
HKCNE2ClarithromycinDrug-induced arrhythmia

Source: Modified from Evans and Relling (Science 286: 487 [2001], as quoted in WHO 2002a).

Note: Table shows examples of genetic polymorphisms that cause unwanted effects of drugs or modification of response. Currently, arrays are being developed for the rapid identification of families of polymorphisms related to infection-defense genotypes, drug-metabolism genotypes, and many others. Although many polymorphisms associated with variations to drug response or toxicity have been defined, the bulk of variation of response to drugs follows a multifactorial pattern of inheritance.

The examples shown are as follows: NAT-2 = N-acetyltransferase; CYP = cytochrome P450; RYR-1 = ryanidine receptor; G6PD = Glucose-6-phosphate dehydrogenase; and ACE = angiotensin-converting enzyme. HERG and HKCNE2 are potassium channels.